PATRONUS RESOURCES LTD

Patronus Biotech (PTN.AX) hits regulatory milestone with first‑human Phase I malaria vaccine trial, positioning a $69.5 M biotech for global impact.

Patronus (PTN.AX) slips 6% as metals & mining stocks fall—find out why the gold‑field explorer’s price trails the 200‑day SMA and how it compares to peers.